/
Other
Newly Diagnosed
75
Pipeline Programs↗
69
Active Trials↗
43
Companies Involved↗
Newly Diagnosed is a moderately active landscape with 75 programs across 43 companies. The most active players are Chipscreen Biosciences, Ltd., Princess Maxima Center for Pediatric Oncology, Sunshine Lake Pharma Co., Ltd.. 33 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 111
Phase 229
Phase 333
Approved
No programs
Analysis
Modality Breakdown
76%
Small molecule
54 of 71 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 71 classified programs, each share of the total. Modality classified for 100% of 75 pipeline programs.
Analysis
Trial Status
173
clinical trials
Recruiting42 · 24%
Completed42 · 24%
Unknown status39 · 23%
Terminated15 · 9%
Active, not recruiting13 · 8%
Not yet recruiting13 · 8%
Other9 · 5%
Clinical Trials
Trial Activity
173 trials
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Recruiting·—·Phase 1·NCT04943848·36 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)